Immunovant, Inc.
IMVTNasdaq
$40.26
↑ +3.3%Jul 17 close · end-of-day
Price
1Y↑ +126.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.3B
Enterprise Value
$6.4B
P/E
—
P/S
—
P/B
8.6
EV/EBITDA
—
PEG
—
FCF Yield
-5.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$505.6M
Free Cash Flow (TTM)
-$407.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-59.3%
ROIC
—
Debt / Equity
—
Net Cash
$902.1M
Return 1Y
+120.2%
Company profile
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.
- CEO
- Peter Salzmann
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- New York
- Website
- immunovant.com
Management & directors
- Gloria MelanieChief Operating Officer
- Stout Jay SChief Technology Officer
- Van Tuyl ChristopherChief Legal Officer
- Venker EricChief Executive Officer
- Girao TiagoChief Financial Officer
- Geffner MichaelChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
IMVT Q4 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.72↑ +14.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | -$107.4M | -$156.7M | -$211.0M | -$259.3M | -$413.8M | -$505.6M |
| Diluted EPS | -$1.22 | -$1.43 | -$1.71 | -$1.88 | -$2.73 | -$2.77 |
| Operating cash flow | -$83.3M | -$106.1M | -$188.2M | -$214.2M | -$375.9M | -$407.3M |
| Free cash flow | -$83.5M | -$106.4M | -$188.4M | -$214.6M | -$376.6M | -$407.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q3 '24 | Q3 '24 | Q3 '24 | Q4 '25 | Q3 '25 | Q3 '25 | Q3 '25 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$87.2M | -$109.1M | -$111.1M | -$106.4M | -$120.6M | -$126.5M | -$110.6M | -$147.9M |
| Diluted EPS | -$0.60 | -$0.74 | -$0.76 | -$0.63 | -$0.71 | -$0.73 | -$0.61 | -$0.72 |
| Operating cash flow | -$76.2M | -$88.6M | -$100.4M | -$110.6M | -$117.4M | -$102.5M | -$92.3M | -$95.1M |
| Free cash flow | -$76.4M | -$88.8M | -$100.6M | -$110.8M | -$117.4M | -$102.5M | -$92.3M | -$95.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Gloria Melanie· Chief Operating Officer | Sale | 1,930 | $39.53 | $76,292.90 | filing |
| 2026-07-08 | Stout Jay S· Chief Technology Officer | Sale | 1,906 | $39.53 | $75,344.18 | filing |
| 2026-07-08 | Stout Jay S· Chief Technology Officer | Sale | 1,399 | $39.53 | $55,302.47 | filing |
| 2026-07-08 | Van Tuyl Christopher· Chief Legal Officer | Sale | 1,143 | $39.53 | $45,182.79 | filing |
| 2026-07-08 | Gloria Melanie· Chief Operating Officer | Sale | 106 | $39.99 | $4,238.94 | filing |
| 2026-07-08 | Stout Jay S· Chief Technology Officer | Sale | 105 | $39.99 | $4,198.95 | filing |
| 2026-07-08 | Stout Jay S· Chief Technology Officer | Sale | 77 | $39.99 | $3,079.23 | filing |
| 2026-07-08 | Van Tuyl Christopher· Chief Legal Officer | Sale | 63 | $39.99 | $2,519.37 | filing |
| 2026-07-02 | Venker Eric· Chief Executive Officer | Sale | 3,092 | $38.48 | $118,980.16 | filing |
| 2026-07-01 | Venker Eric· Chief Executive Officer | D | 86,629 | $38.14 | $3.3M | filing |
| 2026-07-01 | Venker Eric· Chief Executive Officer | Option exercise | 92,188 | $14.46 | $1.3M | filing |
| 2026-06-26 | Stout Jay S· Chief Technology Officer | Sale | 33,277 | $38.18 | $1.3M | filing |
| 2026-06-26 | Van Tuyl Christopher· Chief Legal Officer | Sale | 14,982 | $38.19 | $572,162.58 | filing |
| 2026-06-26 | Gloria Melanie· Chief Operating Officer | Sale | 14,748 | $38.18 | $563,078.64 | filing |
| 2026-06-26 | Girao Tiago· Chief Financial Officer | Sale | 10,000 | $38.46 | $384,600.00 | filing |
| 2026-06-26 | Van Tuyl Christopher· Chief Legal Officer | Option exercise | 17,824 | $15.20 | $270,924.80 | filing |
| 2026-06-26 | Stout Jay S· Chief Technology Officer | Sale | 6,723 | $38.94 | $261,793.62 | filing |
| 2026-06-26 | Girao Tiago· Chief Financial Officer | Option exercise | 10,000 | $15.90 | $159,000.00 | filing |
| 2026-06-26 | Gloria Melanie· Chief Operating Officer | Sale | 2,966 | $38.95 | $115,525.70 | filing |
| 2026-06-26 | Van Tuyl Christopher· Chief Legal Officer | Sale | 2,842 | $38.96 | $110,724.32 | filing |
| 2026-06-26 | Pande Atul | Sale | 1,500 | $38.01 | $57,015.00 | filing |
| 2026-06-26 | Pande Atul | Option exercise | 1,500 | $8.43 | $12,645.00 | filing |
| 2026-06-18 | Van Tuyl Christopher· Chief Legal Officer | Sale | 2,634 | $35.39 | $93,217.26 | filing |
| 2026-06-15 | Pande Atul | Sale | 1,500 | $34.02 | $51,030.00 | filing |
| 2026-06-15 | Pande Atul | Option exercise | 1,500 | $8.43 | $12,645.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.